Moonlake ImmunotherapeuticsMLTX
13F holders, Q1 2025 (March 31)1holders
0new positions
0sold out
$39.07avg. 13F price*
At the end of Q1 2025, 1 institutions reported holding Moonlake Immunotherapeutics (MLTX) in their 13F filings, unchanged from Q4 2024. 0 opened new positions and 0 sold out. The largest holder was Decheng Capital LLC ($6.7M).
- Company
- Moonlake Immunotherapeutics
- CUSIP
- G4444C102
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 1 holders
| Decheng Capital LLC | 1.88% | No change | 171,600 | $6.7M |
"% of holder's portfolio" is MLTX's weight in each manager's 13F, not the share of Moonlake Immunotherapeutics the manager owns.